Illustrative image – not actual.Orchid Chemicals & Pharmaceuticals plans to invest $90 million (Rs.405 crore, approx.) to triple its business over a period of four years.
About $70 million of the proposed funds would be
brought in as equity, while the remaining $20 million would be brought in
through internal accruals of the company.
The company plans to invest funds in areas such as
widening its cephalosporin business, foraying into non-cephalosporin drugs like
central nervous system and cardiovascular drugs, new drug delivery and
discovery systems, formulations and bio-enzymes and bio-transformation
research.
